These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 18938156)

  • 1. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
    Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G
    Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
    Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
    J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
    Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
    Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
    Rix U; Remsing Rix LL; Terker AS; Fernbach NV; Hantschel O; Planyavsky M; Breitwieser FP; Herrmann H; Colinge J; Bennett KL; Augustin M; Till JH; Heinrich MC; Valent P; Superti-Furga G
    Leukemia; 2010 Jan; 24(1):44-50. PubMed ID: 19890374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2. Identification of collagen binding sites in DDR2.
    Leitinger B
    J Biol Chem; 2003 May; 278(19):16761-9. PubMed ID: 12611880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the collagen-binding site of the DDR1 tyrosine kinase receptor.
    Abdulhussein R; McFadden C; Fuentes-Prior P; Vogel WF
    J Biol Chem; 2004 Jul; 279(30):31462-70. PubMed ID: 15136580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discoidin Domain Receptor 1 Inhibitors: Advances and Future Directions for Novel Therapeutics with Aid of DNA Encoded Library Screens and Artificial Intelligence.
    Sanawar R; Sahayasheela VJ; Sarath P; Dan VM
    Mini Rev Med Chem; 2023; 23(15):1507-1513. PubMed ID: 36698236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Cellular and Molecular Mechanism of Discoidin Domain Receptors (DDR1 and DDR2) in Bone Formation, Regeneration, and Its Associated Disease Conditions.
    Mariadoss AVA; Wang CZ
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery.
    Kothiwale S; Borza CM; Lowe EW; Pozzi A; Meiler J
    Drug Discov Today; 2015 Feb; 20(2):255-61. PubMed ID: 25284748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
    Gao M; Duan L; Luo J; Zhang L; Lu X; Zhang Y; Zhang Z; Tu Z; Xu Y; Ren X; Ding K
    J Med Chem; 2013 Apr; 56(8):3281-95. PubMed ID: 23521020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
    O'Hare T; Walters DK; Stoffregen EP; Jia T; Manley PW; Mestan J; Cowan-Jacob SW; Lee FY; Heinrich MC; Deininger MW; Druker BJ
    Cancer Res; 2005 Jun; 65(11):4500-5. PubMed ID: 15930265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
    Deguchi Y; Kimura S; Ashihara E; Niwa T; Hodohara K; Fujiyama Y; Maekawa T
    Leuk Res; 2008 Jun; 32(6):980-3. PubMed ID: 18191450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
    Deadman BJ; Hopkin MD; Baxendale IR; Ley SV
    Org Biomol Chem; 2013 Mar; 11(11):1766-800. PubMed ID: 23247657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
    Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
    Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
    Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
    Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
    Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
    Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.